Cilostazol dosage and administration: Difference between revisions
Ahmed Zaghw (talk | contribs) No edit summary |
|||
| Line 5: | Line 5: | ||
==Dosage And Administration== | ==Dosage And Administration== | ||
The recommended dosage of PLETAL is 100 mg b.i.d. taken at least half an hour before or two hours after breakfast and dinner. A dose of 50 mg b.i.d. should be considered during coadministration of such inhibitors of CYP3A4 as [[ketoconazole]], [[itraconazole]], [[erythromycin]] and [[diltiazem]], and during coadministration of such inhibitors of CYP2C19 as [[omeprazole]]. | The recommended dosage of PLETAL is 100 mg b.i.d. taken at least half an hour before or two hours after breakfast and dinner. A dose of 50 mg b.i.d. should be considered during coadministration of such inhibitors of CYP3A4 as [[ketoconazole]], [[itraconazole]], [[erythromycin]] and [[diltiazem]], and during coadministration of such inhibitors of [[CYP2C19 ]]as [[omeprazole]]. | ||
Patients may respond as early as 2 to 4 weeks after the initiation of therapy, but treatment for up to 12 weeks may be needed before a beneficial effect is experienced. | Patients may respond as early as 2 to 4 weeks after the initiation of therapy, but treatment for up to 12 weeks may be needed before a beneficial effect is experienced. | ||
Revision as of 17:14, 28 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Dosage And Administration
The recommended dosage of PLETAL is 100 mg b.i.d. taken at least half an hour before or two hours after breakfast and dinner. A dose of 50 mg b.i.d. should be considered during coadministration of such inhibitors of CYP3A4 as ketoconazole, itraconazole, erythromycin and diltiazem, and during coadministration of such inhibitors of CYP2C19 as omeprazole.
Patients may respond as early as 2 to 4 weeks after the initiation of therapy, but treatment for up to 12 weeks may be needed before a beneficial effect is experienced.
Discontinuation of Therapy
The available data suggest that the dosage of PLETAL can be reduced or discontinued without rebound (i.e., platelet hyperaggregability).[1]
References
Adapted from the FDA Package Insert.